MSLN and neoplasm: Also, 2 Gy x 2 fractions combined with anti-mesothelin CAR-T cells also significantly improved tumor control (Figure 3D) and survival (Figure 3F2) relative to LDRT alone [p<0.0001]) and CAR-T therapy alone (p<0.0001).